【摘要】 目的评价长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效和成本效用。方法 60例晚期NSCLC患者,每组30例,化疗4周期后,评价疗效和成本效用。结果 NP组和GP组治疗的有效率分别为36.6%和40.0%,中位生存期分别为8.52和8.37月,统计学检验发现两者之间的差异无统计学意义,P>0.05。NP组和GP组治疗的一年生存率分别为36.6%和33.3%;2年生存率分别为16.6%和13.3%,成本效用比分别为1 123.41和1 556.61。结论 NP和GP方案治疗NSCLC疗效基本相似,但NP方案治疗的成本效用相对较好。更多还原

【Abstract】 Objective To compare and evaluate the effectiveness and cost utility of vinorelbine versus gemcitabine combined with cisplatin of advanced non-small cell lung cancer.Methods 60 advanced patients wit NSCLC were enrolled into two groups,the effectiveness and cost utility were evaluated after 2 cycles.Results The efficacy rate wit NP and GP were 36.6 %and 40.0 % respectively,An existence period wit NP and GP were 8.52 and 8.37 respectively,showing no significant difference(P>0.05) between the two groups.One year survival rate with NP and GP were 36.6 %and 40.0 % respectively;two year survival rate with NP and GP were 16.6 %and 13.3% respectively.The ratio of cost utility with NP and GP were 1123.41and 1556.61 respectively.Conclusion The effectiveness of NP versus GP of advanced non-small cell lung cancer was similar,the cost utility of NP was more than GP.更多还原